Home monitoring system assists early detection of nAMD


Ho A, et al. J Clin Med. 2021;doi:10.3390/jcm10071355

Ho reports consulting for and receiving study grants from Notal Vision Inc. Please see the full study for all other authors’ relevant financial disclosures.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]

Early detection of neovascular age-related macular degeneration improved when patients used an at-home monitoring system, according to a review published in the Journal of Clinical Medicine.

Investigators report this system may provide significant benefits to patients with dry AMD.

“The incidence of conversion from dry to neovascular age-related macular degeneration (nAMD) suggests that frequent monitoring of eyes with intermediate AMD would be optimal,” Allen Ho, MD, of Thomas Jefferson University, and colleagues wrote. “However, bringing a large, older population into clinics for monitoring visual and anatomic changes can be difficult for both the patient and the caregivers, particularly given current safety concerns related to the COVID-19 pandemic. One possible solution to address these difficulties is at-home self–monitoring.”

Ho and colleagues conducted a retrospective review of medical records from the Notal Vision Diagnostic Clinic in Manassas, Virginia, of all patients with confirmed conversion from intermediate AMD to nAMD during their participation in a ForeseeHome remote monitoring system program administered between October 2009 and September 2018.

A diagnosis of immediate dry AMD and a best corrected visual acuity of at least 20/60 in any eye that was prescribed served as inclusion criteria. The study comprised 8,991 patients in which a total of 13,930 eyes were tested. The mean age of the patients was 75 years, and most were women (65%). The final analysis showed 306 eyes had converted from intermediate AMD to nAMD.

Sixty-nine percent of the conversions were found after an alert from the ForeseeHome system, while the other 31% was identified at a routine visit.

Ho and colleagues found that 81% of participants in the ForeseeHome group maintained a visual acuity of 20/40 or better at conversion, compared with 34.3% of identified eyes from the IRIS registry dataset using traditional, routine office visits.

“This real-world data analysis confirms that the use of ForeseeHome provides a significant benefit to patients as a means of increasing the early detection of wet AMD when vision is good,” Ho said in a press release about the study. “ForeseeHome can be a useful strategy to monitor at-risk intermediate AMD and help protect vision.”